CompletedNCT01606228
Paliperidone Extended-Release for Schizophrenia: Safety and Tolerability
About this title
A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia
Read the official source — NCT01606228Researchers studied Paliperidone ER to find out how it affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–65
Understand this study
What did researchers investigate?
Researchers studied Paliperidone ER to find out how it affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateDecember 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 188
- Sponsor
- Janssen Pharmaceutica
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01606228
- Official title
Show the full official title
An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly-Dosed Paliperidone ER Among Treatment-Naïve and Newly Diagnosed Patients With Schizophrenia
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
What did researchers investigate?
Researchers studied Paliperidone ER to find out how it affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Janssen Pharmaceutica.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone ER.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia